Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.30 USD
-0.05 (-2.13%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $2.29 -0.01 (-0.43%) 5:04 PM ET
3-Hold of 5 3
F Value A Growth B Momentum B VGM
Income Statements
Fiscal Year end for Taysha Gene Therapies, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15 | 3 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 15 | 3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 88 | 165 | 173 | 43 | 0 |
Income After Depreciation & Amortization | -72 | -162 | -173 | -43 | 0 |
Non-Operating Income | -34 | 0 | 0 | -17 | 0 |
Interest Expense | 5 | 4 | 1 | 0 | 0 |
Pretax Income | -112 | -166 | -175 | -60 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -112 | -166 | -175 | -60 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -112 | -166 | -175 | -60 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -71 | -125 | -173 | -43 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 38 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -72 | -162 | -173 | -43 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 116.12 | 43.95 | 37.65 | 17.67 | NA |
Diluted EPS Before Non-Recurring Items | -0.96 | -3.78 | -4.64 | -3.40 | NA |
Diluted Net EPS (GAAP) | -0.96 | -3.78 | -4.64 | -3.40 | NA |
Fiscal Year end for Taysha Gene Therapies, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.60 | 4.75 | 2.40 | 4.71 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 3.60 | 4.75 | 2.40 | 4.71 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.85 | 21.00 | 25.78 | 21.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.25 | -16.25 | -23.38 | -16.55 |
Non-Operating Income | NA | 64.70 | -99.37 | 0.23 | 0.31 |
Interest Expense | NA | 0.71 | 1.47 | 1.44 | 1.37 |
Pretax Income | NA | 47.74 | -117.09 | -24.60 | -17.62 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 47.74 | -117.09 | -24.60 | -17.62 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 47.74 | -117.09 | -24.60 | -17.62 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 116.12 | 125.70 | 64.25 | 63.26 |
Diluted EPS Before Non-Recurring Items | NA | 0.35 | -0.13 | -0.38 | -0.28 |
Diluted Net EPS (GAAP) | NA | 0.63 | -0.93 | -0.38 | -0.28 |